GALPW Financials Monday, July 14, 2014 12:39:46 PM

GALPW Financials Monday, July 14, 2014 12:39:46 PM
Galena Biopharma, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 2,487 - - -
Cost of Revenue 520 - - -
Gross Profit 1,967 - - -
Operating Expenses
Research and Development 21,076 14,614 3,851 6,046
Sales, General and Admin. 14,600 6,585 8,635 10,579
Non-Recurring Items - - - -
Other 131 - - -
Operating Income (33,840) (21,199) (12,486) (16,625)
Income From Continuing Operations
Add'l Income/Expense Items (40,979) (13,145) 9,086 4,632
Earnings Before Interest and Tax (75,626) (34,377) (3,407) (11,993)
Interest Expense - - - -
Earnings Before Tax (75,626) (34,377) (3,407) (11,993)
Income Tax 1,052 (1,052) - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (76,678) (33,325) (3,407) (11,993)
Non Recurring Events
Discontinued Operations - (1,644) (8,078) -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (76,678) (34,969) (11,485) (11,993)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (76,678) (34,969) (11,485) (11,993)